The company said it entered into separation-related agreements with 3M on March 31, 2024 and became an independent listed company after the pro rata distribution of 80.1% of its common stock to 3M stockholders, effective at 3:30 a.m. Eastern Time on April 1, 2024.

1. 01

   The company said it entered into separation-related agreements with 3M on March 31, 2024 and became an independent listed company after the pro rata distribution of 80.1% of its common stock to 3M stockholders, effective at 3:30 a.m. Eastern Time on April 1, 2024.

2. 02

   The company said that as of the Effective Time, all of its existing executive officers were removed and 8 individuals, including Bryan Hanson (Chief Executive Officer) and Wayde McMillan (Chief Financial Officer), became executive officers.

3. 03

   The company said it expanded and reconstituted its Board to 11 directors as of April 1, 2024 and appointed Carrie S. Cox as Chairman of the Board. Cox will receive a fully vested deferred stock unit grant on or about May 1, 2024, covering a number of shares determined by dividing $400,000 by the closing trading price of Solventum common stock on the grant date.

4. 04

   The company said in its press release that its 2023 sales within 3M were $8.2 billion, and that it has 22,000 employees. Its business segments are Medical Surgical, Dental Solutions, Health Information Systems, and Purification and Filtration.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.